ClinicaliQ Trial Snapshot
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting • Phase III • Oncology • NCT06764485.
- Drug Being Tested: BMS-986365 is being evaluated against standard investigator-selected therapies in a comparative efficacy and safety trial for metastatic castration-resistant prostate cancer (mCRPC).
- Patient Eligibility Overview: The study enrolls patients with confirmed mCRPC who have progressed despite androgen deprivation therapy, with eligibility typically requiring adequate organ function and performance status to tolerate systemic treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Eligibility Snapshot
- * Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. * Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI). * Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be < 4. * Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.